Understanding heroin overdose:A study of the acute respiratory depressant effects of injected pharmaceutical heroin by Jolley, Caroline et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1371/journal.pone.0140995
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Jolley, C., Bell, J., Rafferty, G. F., Moxham, J., & Strang, J. (2015). Understanding heroin overdose: A study of
the acute respiratory depressant effects of injected pharmaceutical heroin. PL o S One , 10(10), [e0140995].
10.1371/journal.pone.0140995
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
RESEARCH ARTICLE
Understanding Heroin Overdose: A Study of
the Acute Respiratory Depressant Effects of
Injected Pharmaceutical Heroin
Caroline J. Jolley1‡*, James Bell2,3‡, Gerrard F. Rafferty1, John Moxham1, John Strang2,3
1 Division of Asthma, Allergy and Lung Biology, Faculty of Life Sciences and Medicine, King’s College
London, King’s Health Partners, Denmark Hill, London, United Kingdom, 2 National Addiction Centre,
Institute of Psychiatry, Psychology and Neuroscience, King’s College London, King’s Health Partners,
Denmark Hill, London, United Kingdom, 3 Addictions Services, South London & Maudsley NHS Foundation
Trust, King’s Health Partners, Denmark Hill, London, United Kingdom
‡CJJ and JB are joint first authors on this work.
* caroline.jolley@kcl.ac.uk
Abstract
Opioids are respiratory depressants and heroin/opioid overdose is a major contributor to the
excess mortality of heroin addicts. The individual and situational variability of respiratory
depression caused by intravenous heroin is poorly understood. This study used advanced
respiratory monitoring to follow the time course and severity of acute opioid-induced respira-
tory depression. 10 patients (9/10 with chronic airflow obstruction) undergoing supervised
injectable opioid treatment for heroin addiction received their usual prescribed dose of
injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral
opioid (methadone or sustained release oral morphine) after 30 minutes. The main outcome
measures were pulse oximetry (SpO2%), end-tidal CO2% (ETCO2%) and neural respiratory
drive (NRD) (quantified using parasternal intercostal muscle electromyography). Significant
respiratory depression was defined as absence of inspiratory airflow >10s, SpO2% < 90%
for >10s and ETCO2% per breath >6.5%. Increases in ETCO2% indicated significant respi-
ratory depression following IOT in 8/10 patients at 30 minutes. In contrast, SpO2% indicated
significant respiratory depression in only 4/10 patients, with small absolute changes in
SpO2% at 30 minutes. A decline in NRD from baseline to 30 minutes post IOT was also
observed, but was not statistically significant. Baseline NRD and opioid-induced drop in
SpO2% were inversely related. We conclude that significant acute respiratory depression is
commonly induced by opioid drugs prescribed to treat opioid addiction. Hypoventilation is
reliably detected by capnography, but not by SpO2% alone. Chronic suppression of NRD in
the presence of underlying lung disease may be a risk factor for acute opioid-induced respi-
ratory depression.
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Introduction
Globally, heroin/opiate overdose is a major cause of death amongst young adults. As the
World Health Organization [1] observes: “Opioids are potent respiratory depressants, and over-
dose is a leading cause of death among people who use them. Worldwide, an estimated 69,000
people die from opioid overdose each year.”Opiates loom large in statistics on drug-related
deaths. In England and Wales, more than 1,700 deaths registered in 2014 (53% of all deaths
from drug poisoning) involved an opiate drug [2]. However, given the very nature of the event,
most research has either been epidemiological (e.g [3, 4]), toxicological (e.g [5]) or post-
mortem (e.g [6]). With the recent establishment of supervised injectable heroin maintenance
clinics (see description in Lancet 2010 [7] and recent meta-analysis [8]), an opportunity exists
to study physiological responses to intravenous and intramuscular administration of extremely
high dose diamorphine (e.g. 50–200mg) in a clinical context, but with the addition of compre-
hensive monitoring of acute changes in respiratory function.
Evidence from international trials suggests that injectable opioid treatment (IOT) pro-
vided in supervised clinics can be an effective intervention for patients who fail to respond
to oral methadone treatment for heroin addiction. These trials have demonstrated that
in methadone non-responders, injectable treatment can markedly reduce use of street
drugs and contribute to improvements in health and wellbeing. By guaranteeing prompt
treatment in the event of acute respiratory depression, directly supervised opioid
treatments also offer additional security compared to continued illicit opioid use on the
street. However, injectable trials have consistently reported a higher incidence of serious
adverse events—notably, respiratory depression—associated with injectable compared
to oral treatment [7, 9–13]. The risk of respiratory depression is greatest if patients have
concomitantly taken benzodiazepines or alcohol, or during induction while tolerance to opi-
oids is being increased. The great majority of adverse events occur within a few minutes of
injection, leading some clinicians to suggest that all patients treated in injectable clinics
should be monitored for 15 minutes after every injection [14]. Standard practice involves
monitoring for hypoventilation using pulse oximetry. It is unknown, however, whether
other approaches to monitoring, such as transcutaneous or end-tidal CO2 monitoring, or
more direct measures of neural respiratory drive (NRD) such as respiratory muscle electro-
myography [15–18] provide a more sensitive and earlier indicator of respiratory depression
in these patients.
The aim of this study was to investigate the time course and severity of respiratory depres-
sion following acute administration of injected and oral opioids in opioid-tolerant subjects.
Specifically, we aimed to investigate the use of a combination of pulse oximetry, end-tidal CO2
monitoring, and parasternal intercostal muscle electromyogram recordings (EMGpara) to
detect acute reductions in neural respiratory drive (NRD) to determine the added value of
advanced physiological monitoring over pulse oximetry alone.
Methods
Ethical approval
The study was approved by the Clinical Governance Committee, South London and Maudsley
Addictions Clinical Academic group, and was conducted according to the principles expressed
in the Declaration of Helsinki. Consent was given orally and recorded in the patient’s clinical
notes, as approved by the Clinical Governance Committee.
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data collection and analysis, decision to publish, or
preparation of the manuscript.
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Inclusion and exclusion criteria
Inclusion criteria.
1. Receiving injectable opioid treatment for heroin addiction by South London and Maudsley
NHS Foundation Trust, on a stable dose regime for at least 2 weeks;
2. Age>/ = 18 years;
3. Capacity to provide informed consent.
Exclusion criteria.
1. Acute drug or alcohol intoxication or delirium tremens;
2. Inability to reliably perform physiological tests of respiratory function;
3. Concomitant benzodiazepine use.
Participants
10 patients took part in the study. Participants’ age, height, weight and body mass index (BMI)
were documented. Spirometry (forced expiratory volume in 1 second (FEV1) and slow vital
capacity (VC)) were measured and reported as FEV1% predicted, VC% predicted and FEV1%VC.
Protocol
Each participant attended the respiratory unit and had monitoring equipment fitted. Once
comfortable, and having had baseline observations performed, participants received their pre-
scribed dose of injectable opioid (at t = 0 minutes). Each participant was then monitored over a
period of 150 minutes after intravenous and intramuscular high-dose diamorphine (pharma-
ceutical heroin), with the dose having previously been determined in the context of their addic-
tion treatment. EMGpara and pulse oximetry (SpO2%) were monitored continuously over the
study duration. At 3 minutes prior to administration of the injectable opioid, and then at 3, 8,
15, 30, 60, 105 and 150 minutes each participant was asked to rate their subjective feeling of
drug effect using a visual analogue scale, and one-minute averages of end tidal CO2%
(ETCO2%) and airflow were recorded. At these times pupil size was also recorded, and a staff
rating of level of consciousness and intoxication were also documented.
Measurements
All physiological signals were acquired, digitised and analysed using a Powerlab analog-to-
digital converter (ADInstruments Pty Ltd, Castle Hill, Australia) on a laptop computer (Apple
Computer Inc, Cupertino, CA USA) running LabChart Pro software (LabChart 7 Pro version
7.3.7, ADInstruments Pty Ltd, Castle Hill, Australia). Data were stored for offline analysis
using LabChart 7 Pro.
Parasternal intercostal muscle electromyogram recordings (EMGpara). EMGpara was
recorded using bipolar surface electrodes (Kendall Arbo1, Tyco Healthcare1, Neustadt.Ger-
many) applied bilaterally in the second intercostal space, 3cm from the midline, as previously
described [19]. EMGpara signals were amplified and band-pass filtered between 10 Hz and
3 kHz (Biomedical amplifier Pclab-3808, Guangzhou Yinghui Medical), and acquired and digi-
tized at a sampling frequency of 2kHz with additional digital band-pass filtering between 20Hz
and 1kHz for EMG analysis. Peak root mean square per breath was calculated and expressed as
Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin
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a percentage of the maximum EMG (EMGpara%max) obtained during three maximal voli-
tional manoeuvres: inspiration to total lung capacity, maximal static inspiratory pressure
manoeuvre and a maximal sniff manoeuvre [17]. To incorporate the combined effect of opioids
on neural respiratory drive (NRD) per breath and respiratory rate, the “EMGpara%index” was
calculated as the product of EMGpara%max and respiratory rate (Vf).
Ventilation. Airflow was measured through a mouthpiece connected in series to a Fleisch
pneumotachograph with a noseclip in place. Tidal volume per breath (VT) was calculated off-
line as the integral of the flow signal. Minute ventilation (VE) was calculated as the product of
the average VT and Vf.
SpO2% and ETCO2%. SpO2% was recorded by pulse oximetry (Ohmeda Biox 3700).
SpO2% was consistently increased upon breathing through the pneumotachograph during the
intermittent measures of ventilation. Hence SpO2% for each timepoint was reported as the
average of data over the 30 second period immediately preceding the time at which the pneu-
motachograph was introduced.
ETCO2% was measured as the peak %CO2 per expired breath using a capnograph (GA-200,
iworx, New Hampshire, US) which sampled continuously from using a fine bore catheter
pneumotachograph.
Indicators of significant respiratory depression. Recordings were examined for evidence
of the following indices of significant respiratory depression: absence of inspiratory airflow for
more than 10 seconds, SpO2< 90% for more than 10 seconds and ETCO2% per breath exceed-
ing 6.5%. Participants were stimulated with verbal and/or painful stimuli if apnoea
persisted> 15 seconds.
Subjective drug effect. Staff rating of intoxication was measured on a visual analogue
scale:
Rating of intoxication 0 = no effect, 5 = maximal effect
Staff level of consciousness was assessed using a numerical rating scale:
1 = normal, 2 = visibly affected but alert, 3 = drowsy but responds to verbal stimuli, 4 = no
response to verbal stimuli
Patients assessed their drug-related “high” on a visual analogue scale:
Rating of intoxication 0 = no effect, 5 = maximal effect
Statistics. Statistical analysis was performed using GraphPad Prism 5 for Windows v5.00
(GraphPad Software, Inc). Data are presented as the median and interquartile range unless oth-
erwise stated. Differences between physiological variables between baseline and successive
timepoints after drug administration were assessed using 1 way ANOVA (Friedman test), with
post hoc analysis using Dunn’s Multiple Comparison Test. Statistical significance levels were
set at p<0.05.
Results
Demographic and anthropometric data, lung function and baseline levels of EMGpara%max
and EMGpara% index are shown in Table 1.
Nine of the 10 participants had chronic obstructive pulmonary disease (COPD) by spiro-
metric and clinical criteria. Only one participant had previously been diagnosed with COPD
and had been prescribed inhaled short-acting beta-2-agonists. This participant reported infre-
quent use of inhaled treatment, and had not used inhalers on the day of testing. Seven partici-
pants were taking additional prescribed medication as follows: mirtazapine 45mg once daily
only (2 patients); fluoxetine 20mg once daily only (2 patients); zopiclone 7.5mg tablet nocte
and co-codamol 8mg/500mg tablets as required (1 patient); beta blocker (not specified) and
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omeprazole (1 patient); amitriptyline 75mg once daily and fluoxetine 20mg once daily (1
patient).
Periodic breathing was evident from the SpO2%, airflow and EMGpara traces before admin-
istration of study drugs in eight of the ten participants.
All participants completed 30 minutes of recording after administration of an injectable opi-
oid (three by intravenous injection; seven by intramuscular injection), and nine of the ten sub-
jects took an oral opioid. The majority of patients chose to finish the study before the intended
150 minutes, citing other time commitments as the reason for early departure. The median
time spent undergoing recordings after administration of an oral opioid was 60 minutes (range
50 to 120 minutes), with only one participant completing the study to the planned 150 minutes
post injectable opioid.
Summary of main respiratory effects
The impact of injection (given at T0) and of oral methadone (administered 30 minutes later) is
shown in Fig 1 and Table 2.
After injectable rather than oral opioids, most patients (eight) were observed to experience
at least one of the indicators of respiratory depression for which monitoring was performed
(Table 2). In six of the participants, at least two of these indicators were seen. Over the duration
of the study, the median (range) nadir of SpO2% was 88.3% (73.6 to 92.6) and the median
(range) peak ETCO2% per breath was 6.9% (5.2 to 7.8). Oxygen desaturation was mostly peri-
odic, but the average SpO2% was significantly lower at 15 minutes post injectable opioid (base-
line SpO2 96.5 (95.1 to 99.2)% to 95.3 (90.9 to 98.4)% at 15 minutes, p = 0.03). However,
SpO2% frequently remained close to baseline (pre injectable opioid) levels despite significant
reductions in neural respiratory drive as indicated by a fall in EMGpara activity (Fig 2).
There was a significant inverse relationship between EMGpara%index at baseline and the
magnitude of the opioid-induced drop in SpO2 from baseline (Spearman r = -0.67, p = 0.04),
i.e. opioid-induced oxygen desaturation was greater in participants with lower levels of neural
respiratory drive at baseline (Fig 3).
Table 1. Demographic and anthropometric data, spirometry and EMGpara data of the 10 participants.
Median Interquartile range
Age (years) 49 42 to 58
Sex (M/F) 8/2
Height (m) 1.75 1.62 to 1.81
Weight (kg) 65.6 54.8 to 76.4
BMI (kg/m2) 21.6 19.3 to 25.3
FEV1 (L) 2.30 1.48 to 3.78
FEV1%predicted 76.0 54.0 to 95.5
VC (L) 4.80 2.98 to 5.53
VC % predicted 115.0 101.5 to 116.3
FEV1/VC% 58.5 39.6 to 66.1
EMGpara%max (%) 8.20 6.53 to 18.42
EMGpara%index (a.u.) 109.5 69.5 to 185.1
Data are presented as the median and interquartile range. M = male, F = female, BMI = body mass index,
FEV1 = forced expiratory volume in 1 second, VC = vital capacity, EMGpara%max = parasternal
electromyogram activity per breath as a proportion of maximum, EMGpara%index = EMGpara%
max*respiratory rate, a.u. = arbitrary units.
doi:10.1371/journal.pone.0140995.t001
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Acute effects of injectable opioids on neural respiratory drive and
ventilation
EMGpara%index declined at a variable rate from baseline (baseline EMGpara%index 109.5
(69.5 to 185.1) arbitrary units (a.u.) to 84.3 (59.2 to 118.1) a.u. at 30 minutes, p = 0.12, accom-
panied by significant increases in ETCO2% (median (IQR) baseline ETCO2% 4.7 (4.5 to 5.4)%
to 5.4 (5.1 to 5.7)% at 30 minutes, p = 0.01) (Fig 1). In participants with baseline levels of EMG-
para%max above the normal range (participants #1, #3 and #4 with levels of EMGpara%max of
Fig 1. Physiological effects of injectable opioids on individual participants.One-minute averages of physiological data for each of the 10 individuals at
baseline (0 minutes) and 3 minutes, 8 minutes, 15 minutes and 30 minutes after injectable opioid administration. VT = tidal volume, VE = minute ventilation, Vf
= respiratory rate, SpO2% = oxygen saturation measurement determined by pulse oximetry, ETCO2% = end tidal breath carbon dioxide concentration (%).
doi:10.1371/journal.pone.0140995.g001
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Table 2. Dosage, routes of administration, episodes of respiratory depression following injected and oral opioid medication for each participant.
ID Drug T0 Resp pause
>10s
SpO2 <90% for
>10s
ETCO2 >
6.5%
Oral opioid T30 Resp pause
>10s
SpO2 <90% for
>10s
ETCO2 >
6.5%
1 diamorphine 50mg
IV
methadone
80mg
✓
2 diamorphine 60mg
IV
None a a a
3 diamorphine 90mg
IM
✓ ✓ methadone
50mg
✓ ✓
4 diamorphine 100mg
IM
✓ SROM 700mg
5 diamorphine 200mg
IM
✓ methadone
100mg
✓
6 diamorphine 160mg
IM
✓ ✓ methadone
80mg
✓
7 diamorphine 100mg
IV
✓ ✓ ✓ SROM 600mg ✓ ✓ ✓
8 diamorphine 200mg
IM
✓ ✓ methadone
100mg
9 methadone 100mg
IM
methadone
100mg
10 diamorphine 160mg
IM
✓ ✓ methadone
100mg
✓ indicates the occurrence of the corresponding adverse event.
a indicates data not collected.
ID = patient identiﬁcation number. T0 = baseline. T30 = 30 minutes after injected opioid. “0–30” indicates the time period between T0 and T30. “30–60”
indicates the time period between T30 and 60 minutes post injected opioid. Resp pause > 10s = absence of inspiratory airﬂow for more than 10s.
IM = intramuscular injection. IV = intravenous injection. SROM = sustained release oral morphine.
doi:10.1371/journal.pone.0140995.t002
Fig 2. Airflow, parasternal electromyogram activity (EMGpara), ETCO2% and SpO2% in an individual subject (#4) at baseline and at 30 minutes
after intramuscular diamorphine injection. Airflow, parasternal electromyogram activity (EMGpara), ETCO2% and SpO2% in an individual subject (#4) at
baseline and at 30 minutes after intramuscular administration of 100mg diamorphine. Note substantial reductions in EMGpara activity per breath despite
relatively little change in airflow, respiratory rate, ETCO2% and SpO2%.
doi:10.1371/journal.pone.0140995.g002
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34.0%. 18.7% and 18.4% respectively), reductions in EMGpara activity following injectable opi-
oid were proportionally greater than reductions in ventilation (Fig 2).
Acute effects of oral opioids on neural respiratory drive and ventilation
Nine patients received an oral opioid. The median (IQR) maximum one-minute average of
ETCO2% recorded after oral opioid administration was 5.8 (4.8 to 6.2)%. The minimum one-
minute averages of SpO2%, VE, EMGpara%max and EMGpara%index were 94.7 (92.9 to
95.9)%, 9.0 (7.5 to 13.4) L/min, 9.3 (6.6 to 13,3)% and 108.7 (67.4 to 117.3) a.u. respectively.
Thus relatively little absolute change in respiratory variables was observed after oral opioid
administration above any residual effect of injectable opioid after 30 minutes, although reduc-
tions in one-minute averages of EMGpara%index were observed in four participants.
Participant- and observer-reported effects of opioids
Significant changes compared to baseline (t = 0) were reported in observer-reported pupil size
and participant-reported subjective “high” 8-minutes after injected opioids. Changes reported
after oral opioid administration were not significant. There were no statistically significant
changes in level of consciousness or intoxication following injected or oral opioid administra-
tion (Table 3).
Discussion
Principal findings
Significant respiratory suppression was found to occur commonly in the acute period following
administration of injectable and oral opioid drugs in opioid-tolerant addicts. Our advanced
respiratory monitoring protocol, in particular a combination of pulse oximetry and capnogra-
phy, was able to detect changes that would have been under-recognised by standard clinical
Fig 3. The relationship between baseline EMGpara%index and the magnitude of the maximum change
in SpO2% from baseline.Data shown are for each individual participant. r = Spearman coefficient; a.u. =
arbitrary units.
doi:10.1371/journal.pone.0140995.g003
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monitoring protocols using pulse oximetry alone. Subjective observer ratings of drug effect
were found to be unreliable markers of physiological effect. We also observed an inverse rela-
tionship between baseline EMGpara%index and opioid-induced hypoxaemia.
Strengths and weaknesses of the study
The main strength of the study is that it is the first to document the degree of acute opioid-
induced respiratory depression induced in heroin addicts using capnography, and respiratory
muscle electromyography which is a quantifiable and more direct measure of NRD than stan-
dard pulse oximetry alone. One weakness of the study is the small relatively sample size. How-
ever, this is a challenging group of patients on whom to carry out detailed physiological
studies, with a small potential cohort of around 40 patients enrolled in such clinics at one time.
We were unable to include a group of patients without chronic respiratory disease, which
would have provided further information to better define the profile of patients at higher risk
of respiratory depression when in treatment. This should be a focus of future studies. Patients
awaiting their scheduled injection of diamorphine tend to be in an aroused state, and although
every attempt was made to relax participants as much as possible, a tendency to hyperventila-
tion was evident in some at baseline. Post-injection, although participants were encouraged to
sit as quietly as possible for the measurements, this was not consistently adhered to and, it was
not possible to analyse blocks of data that were contaminated by patients talking or moving.
Monitoring ETCO2% involves a degree of measurement artefact, as the stimulation of having a
mouthpiece in place tended to stimulate breathing [20]. Indeed, the inconvenience of the
mouthpiece made it impossible to monitor ETCO2 continuously over a number of hours. End-
tidal CO2 measurements also often underestimate true arterial CO2 in patients with chronic
airflow obstruction and emphysema, reflecting the ventilation-perfusion abnormalities associ-
ated with the underlying lung disorder. However the use of ETCO2% measurement did allow
monitoring of acute changes in CO2 on a breath-by-breath basis. Although transcutaneous
monitoring of pCO2 would have allowed continuous monitoring to be undertaken, this would
have been at the expense of a slower response time. Finally, patients did not routinely undergo
urine toxicology screening prior to testing to verify that participants were abstinent from addi-
tional non-prescribed/illicit drugs that could alter respiratory drive, for example benzodiaze-
pines, cocaine and amphetamines.
Comparisons with other studies
It is well-known that the μ-opioids diamorphine, morphine and methadone depress respira-
tion, at least in part, through a direct effect on the brainstem respiratory centres [21]. Both
Table 3. Participant-rated drug-related “high”, and observer-rated responses to injected and oral opioids.
Minutes post injected opioid Post oral opioid
0 3 8 15 30 >60 mins
Pupil size (mm) 4.0 (3.0 to 7.0) 3.0 (2.0 to 4.0) 2.5 (2.0 to 3.0)* 2.75 (2.0 to 3.0)* 3.0 (2.0 to 3.25) 3 (2.25 to 3.0)
Consciousness 1.0 (1.0 to 1.0) 1.0 (1.0 to 1.25) 1.0 (1.0 to 1.25) 1.0 (1.0 to 2.25) 1.0 (1.0 to 2.0) 1 (1.0 to 1.0)
Subjective high 0.0 (0.0 to 0.0) 1.5 (0.0 to 2.63) 2.0 (1.0 to 2.25)* 2.0 (1.0 to 2.25)* 2.0 (1.0 to 2.25)* 1.0 (0.0 to 2.0)
Intoxication (observer-rated) 0.0 (0.0 to 0.0) 1.0 (0.0 to 2.25) 1.0 (0.0 to 3.25) 1.5 (0.0 to 3.25) 2.0 (0.75 to 4.0) 1.0 (0.0 to 2.5)
Higher numbers on scales for consciousness, subjective high and level of intoxication indicate greater drug-related effects (refer to Methods section for full
details).
* indicates a statistically signiﬁcant change compared to baseline (t = 0), at the 0.05 level
doi:10.1371/journal.pone.0140995.t003
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acute [22] and chronic [23] opioid use decrease the hypercapnic and hypoxic ventilatory
responses in humans. The minimum SpO2% observed in the present study of 88.3 (73.6 to
92.6)% is in keeping with the findings of previous studies undertaken within supervised inject-
ing clinics [24–26]. There was evidence of varying degrees of respiratory depression in all par-
ticipants, particularly after injected diamorphine, and 8/10 participants experienced apnoeic
episodes or prolonged episodes of significant hypoxaemia. It was observed that SpO2% levels
within the “normal” baseline range for an individual did not reliably exclude the presence of
opioid-induced reductions in NRD, or increased ETCO2% in keeping with opioid-induced
hypoventilation. Using airway occlusion pressure at 100ms (P0.1) to monitor NRD, acute opi-
oid-induced decreases in NRD have been observed in surgical populations both with [27] and
without [28] detectable changes in gas exchange. Previous studies in opioid-naive obstetric and
surgical populations, monitoring transcutaneous pCO2 [29, 30] or end-tidal CO2 [31], have
also documented hypercapnia in the presence of normal respiratory rates and oxygen satura-
tion. SpO2% remained within the normal range (average SpO2% 98%) in healthy volunteers
receiving intravenous remifentanyl despite an average 30% decrease in respiratory rate [32].
Furthermore, acute relief of breathlessness by opioids in palliative care can be achieved with a
reduction in respiratory rate but minimal change in SpO2% or pCO2 [33, 34]. There is no expe-
rience of the use of more direct measures of NRD to identify episodes of opioid-induced respi-
ratory depression. Work by our group [15, 17, 18, 35, 36] and others [19, 37–39] has shown
that quantification of the electromyogram (EMG) of the obligate inspiratory muscles, in partic-
ular the diaphragm (EMGdi) and parasternal intercostal muscles (EMGpara), provides a reli-
able measure of NRD. In patients with respiratory disease, disordered pulmonary mechanics
limit translation of NRD to ventilatory output. In such patients, EMGdi and EMGpara provide
a more sensitive marker of changes in NRD than respiratory muscle pressure generation or
ventilation [17, 38]. Since there is a high prevalence of smoking [40], chronic obstructive pul-
monary disease (COPD) and related respiratory disorders [41] in patients undergoing treat-
ment for drug addiction, EMGpara has potential benefits over the use of ventilation-derived
indices as a physiological biomarker of NRD in this patient population.
Explanations and implications of the findings
Pulse oximetry and observer-rated levels of drug effect under-estimate the true respiratory
depressant effect of opioids. Clinically-available monitoring systems, comprising of pulse
oximetry, respiratory rate and even end-tidal CO2, cannot be fully relied upon to detect the
extent of acute opioid-induced respiratory depression. Of note, simply speaking to patients
who were having prolonged apnoeic spells was enough stimulation to prompt them to resume
breathing. Rousing someone to put a clip on their finger, or simply talking to patients post
injection, may mask episodes of hypoxia.
Even though this was a small study in a heterogeneous population, including participants
on different oral opioids and variable parenteral doses, acute opioid-induced respiratory
depression was evident in all study participants to a greater or lesser degree (Fig 1 and Table 2).
Thus tolerance to opioids does not seem to fully protect against respiratory depression, which
importantly implies that even well-stabilised patients are at risk. Co-administration of addi-
tional central nervous system depressants, such as benzodiazepines and alcohol, is a major con-
tributor to heroin-related deaths [42], and would be expected to potentiate the opioid-induced
respiratory depression observed here.
Patients with lower levels of NRD at baseline exhibited a greater reduction in SpO2 follow-
ing opiate administration. Levels of EMGpara%max of 8.20 (6.53–18.4) % fall within the range
reported in healthy adults [17, 43], below the levels reported in patients with chronic
Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin
PLOS ONE | DOI:10.1371/journal.pone.0140995 October 23, 2015 10 / 14
obstructive lung disease [17, 18, 35]. A combination of chronic suppression of NRD by long-
term opioids and other CNS depressants, coupled with the progression of lung and other sys-
temic disease, could go some way to explaining the observed higher rate of opioid overdose
deaths in older cohorts of opioid addicts [44, 45]. Interestingly, in participants with relatively
high levels of EMGpara activity at baseline, in keeping with the presence of COPD and/or
other structural lung disease [17, 35], the magnitude of acute decreases in NRD was propor-
tionally greater than reductions in ventilation, SpO2 and ETCO2%. This can be explained by
considering the degree of neuroventilatory uncoupling in these patients. In the presence of
altered pulmonary mechanics associated with chronic lung disease, there is significant uncou-
pling of ventilation from NRD, such that increases in motor efferent command to the respira-
tory muscles cannot be translated to effective changes in respiratory muscle pressure
generation or ventilation. In COPD, increases in NRD, e.g. during exercise, occur with rela-
tively little increase in ventilation or associated physiological parameters after a threshold level
of neuroventilatory uncoupling is reached [17, 35, 38, 46]. It is conceivable that a similar phe-
nomenon occurs when NRD is reduced back down the NRD-ventilation relationship curve by
opioids, such that reductions in NRD are not accompanied by changes in ventilatory output
until a threshold of relative neuroventilatory “recoupling” is achieved.
Unanswered questions and future research
In this study we have demonstrated that acute opioid-induced respiratory depression in opi-
oid-tolerant addicts can be detected using continuous advanced respiratory monitoring tech-
niques, and that these adverse drug effects are likely to be under-recognised using standard
monitoring protocols. It remains unanswered, both within the field of addiction or in general
medical settings, whether more intensive respiratory monitoring can reduce the risk of signifi-
cant opioid-associated respiratory depression. The findings of our study highlight the need for
careful physiological studies of the mechanisms of overdose in heroin addiction.
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